Opportunistic infections in paediatric inflammatory bowel disease patients

Archives of Disease in Childhood

Volumn 97, Issue 1, 2012, Pages 5-7

  De Greef, Elisabeth ^a   Vandenplas, Yvan ^a   Veereman Wauters, Gigi ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; MEASLES VACCINE; MERCAPTOPURINE; METHOTREXATE; MUMPS VACCINE; NATALIZUMAB; PREDNISONE; RUBELLA VACCINE;

ANTIVIRAL THERAPY; BACTEREMIA; CANDIDIASIS; CHEMOPROPHYLAXIS; CHILD; COCCIDIOIDOMYCOSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; ESCHERICHIA COLI INFECTION; HEMORRHAGIC COLITIS; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; ILEITIS; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LEISHMANIASIS; LISTERIOSIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MENINGITIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SALMONELLOSIS; SEPSIS; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; AGED; CHILD; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

EID: 84455195578     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2011-300365     Document Type: Review

References (52)

1. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2010;17:423-39.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. (Pubitemid 34851835)
3. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30. (Pubitemid 47309975)
4. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
5. Burgmeijer R, Hoppenbrouwers K, Bolscher N. Immunosuppressieve therapie. In: Gorcum V, ed. Handboek Vaccinaties. Assen: Van Gorcum, 2007:135.
6. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1124-9. (Pubitemid 44311642)
7. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
8. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30. (Pubitemid 30346978)
9. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-6.
10. Osterman MT, Lichtenstein GR. Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol 2007;10:195-207. (Pubitemid 46938929)
11. Armbrust W, Kamphuis SS, Wolfs TW, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2004;43:527-9. (Pubitemid 38489378)
12. Hunstad DA, French AR. Histoplasmosis in a child with JRA on low-dose methotrexate. Rheumatology (Oxford) 2007;46:177-8. (Pubitemid 44932808)
13. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504. (Pubitemid 351705939)
14. Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis- factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010;25:1732-8.
15. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36. (Pubitemid 351451967)
16. Fidder H, Schnitzler F, Ferrante M, et al. Longterm safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8.
17. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91.
18. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
19. Aberra FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 2007;5:1070-5.
20. Izbéki F, Nagy F, Szepes Z, et al. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease. Inflamm Bowel Dis 2008;14:429-31. (Pubitemid 351441336)
21. Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol 2005;16:289-92. (Pubitemid 41719722)
22. Dederichs F, Pinciu F, Gerhard H, et al. [Listeria meningitis in a patient with Crohn's disease-a seldom, but clinically relevant adverse event of therapy with infliximab]. Z Gastroenterol 2006;44:657-60.
23. Osuna Molina R, Ferrer Ríos T, Gallego Gallegos R, et al. [Listeria meningitis as complication of treatment with infliximab in a patient with Crohn's disease]. Rev Esp Enferm Dig 2006;98:60-1.
24. Ramanampamonjy RM, Laharie D, Bonnefoy B, et al. [Infliximab therapy in Crohn's disease complicated by Listeria monocytogenes meningoencephalitis]. Gastroenterol Clin Biol 2006;30:157-8.
25. Joosten AA, van Olffen GH, Hageman G. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy]. Ned Tijdschr Geneeskd 2003;147:1470-2.
26. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74. (Pubitemid 41132341)
27. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81. (Pubitemid 41132342)
28. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8. (Pubitemid 41132340)
29. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
30. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33. (Pubitemid 46608637)
31. Schett G, Herak P, Graninger W, et al. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol 2005;43:2537-41. (Pubitemid 40656290)
32. Rachapalli S, O'Daunt S. Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept. Arthritis Rheum 2005;52:987. (Pubitemid 40365125)
33. Nadarajah K, Pritchard C. Listeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritis. J Clin Rheumatol 2005;11:120-2. (Pubitemid 40577961)
34. La Montagna G, Valentini G. Listeria monocytogenes meningitis in a patient receiving etanercept for Still's disease. Clin Exp Rheumatol 2005;23:121. (Pubitemid 40424771)
35. Pagliano P, Attanasio V, Fusco U, et al. Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis? Ann Rheum Dis 2004;63:462-3. (Pubitemid 38453319)
36. Bowie VL, Snella KA, Gopalachar AS, et al. Listeria meningitis associated with infliximab. Ann Pharmacother 2004;38:58-61. (Pubitemid 38018007)
37. Kesteman T, Yombi JC, Gigi J, et al. Listeria infections associated with infliximab: case reports. Clin Rheumatol 2007;26:2173-5. (Pubitemid 350120364)
38. de la Fuente Penco B, Marco Piella A, Riera Mestre A, et al. [Sepsis caused by Listeria monocytogenes related with the use of infliximab]. Med Clin (Barc) 2005;124:398.
39. Makkuni D, Kent R, Watts R, et al. Two cases of serious food-borne infection in patients treated with anti-TNF-alpha. Are we doing enough to reduce the risk? Rheumatology (Oxford) 2006;45:237-8. (Pubitemid 43160097)
40. Katsarolis I, Tsiodras S, Panagopoulos P, et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005;37:304-5. (Pubitemid 40542779)
41. Rijkeboer A, Voskuyl A, Van Agtmael M. Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist. Scand J Infect Dis 2007;39:80-3. (Pubitemid 46277154)
42. Netea MG, Radstake T, Joosten LA, et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7. (Pubitemid 36828680)
43. Fu A, Bertouch JV, McNeil HP. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis Rheum 2004;50:3049. (Pubitemid 39209546)
44. Goode S, Tierney G, Deighton C. Life threatening intra-abdominal sepsis in patients on anti-TNF-alpha therapy. Gut 2006;55:590-1.
45. Kirchgatterer A, Weber T, Hinterreiter M, et al. Haemorrhagic colitis due to Escherichia coli O103:H2 associated with infliximab therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:355-6. (Pubitemid 34537881)
46. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24. (Pubitemid 36277998)
47. Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009;28:331-7.
48. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13. (Pubitemid 38447195)
49. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008;57:1393-7.
50. Recommended childhood and adolescent immunization schedules - United States, 2009. Pediatrics 2009;123:189-90.
51. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851-6. (Pubitemid 47031059)
52. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549-58. (Pubitemid 351442541)